The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research shows the therapy comes with the risk of cardiovascular problems in a higher than expected percentage of patients.
from Top Health News – ScienceDaily http://bit.ly/2E81aD3
from Tumblr http://bit.ly/2DrLR6L
No comments:
Post a Comment